Article

Pharmaceutical Executive

Pharmaceutical Executive

Pharmaceutical Executive-07-01-2001
Volume0
Issue 0

Pharmacies: OTC Price Wars

Author(s):

Kevin Gopal

London, United Kingdom-The UK OTC trade association supports the Community Pharmacy Action Group (CPAG) in its decision to withdraw a court case regarding the price-fixing of OTC drugs after the judge said there was little evidence that abolition of price maintenance would harm community pharmacists. The withdrawal brings an end to a long-running court battle pitting the pharmaceutical industry against an equally powerful corporate enemy, the supermarkets.

Articles in this issue
Pharmacies: OTC Price Wars
One Disease at a Time
Overview of the Industry: A World of Opportunities
The Power Shift
A Giant Stumbles
Overruled: No More Dual Pricing
Submerged
Generic Threat

Newsletter

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Subscribe Now!
Related Videos
Gen Li
Robert Lisicki
Gen Li
Gen Li
Dr. Ben Zeskind
Gen Li
Dr. Ben Zeskind
Gen Li
Related Content
Early Trial Success Signals Promise for GT-02287 in Parkinson’s Disease Treatment
August 2nd 2025

Early Trial Success Signals Promise for GT-02287 in Parkinson’s Disease Treatment

Don Tracy, Associate Editor
Gene Mack, CEO, GAIN Therapeutics, shares how growing clinician confidence and strong early experiences helped accelerate enrollment in the company’s Phase Ib Parkinson’s disease trial.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
August 2nd 2025

Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research

Miranda Schmalfuhs
LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Stock.adobe.com
August 2nd 2025

Pharma Industry Execs React to President Trump’s 60-Day MFN Deadline

Mike Hollan
Members of the industry believe the US should remain an innovation-friendly market.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
August 2nd 2025

Beyond the Prescription: Pharma's Role in Digital Health Conversations

Canopy
Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Merck to Cut 6,000 Jobs as It Aims for $3 Billion in Cost Savings by 2027
August 2nd 2025

Merck to Cut 6,000 Jobs as It Aims for $3 Billion in Cost Savings by 2027

Don Tracy, Associate Editor
Facing patent expiration for its blockbuster Keytruda, Merck aims to streamline operations with significant job cuts and continued R&D investments.
FDA Approves Label Update for Novartis’ Leqvio to Enable Twice-Yearly Monotherapy for LDL-C Management in Adults with Hypercholesterolemia
August 2nd 2025

FDA Approves Label Update for Novartis’ Leqvio to Enable Twice-Yearly Monotherapy for LDL-C Management in Adults with Hypercholesterolemia

Don Tracy, Associate Editor
The updated label no longer requires Leqvio (inclisiran) to be used in combination with statins for low-density lipoprotein cholesterol management.